Literature DB >> 3670348

Outbreak of severe hepatitis due to delta and hepatitis B viruses in parenteral drug abusers and their contacts.

L A Lettau1, J G McCarthy, M H Smith, S C Hadler, L J Morse, T Ukena, R Bessette, A Gurwitz, W G Irvine, H A Fields.   

Abstract

We investigated an unusually large and severe outbreak of hepatitis B, primarily involving parenteral drug abusers and their sexual contacts, in Worcester, Massachusetts, over a 21-month period from 1983 to 1985. Of 135 patients with drug-related acute hepatitis B, 81 percent were parenteral drug abusers and 19 percent had sexual contact with drug abusers; 13 fulminant cases resulted in 11 deaths. Among the patients with hepatitis B, evidence of delta virus infection was found in 54 percent of drug abusers, 33 percent of their sexual contacts, and 9 percent of other patients with acute hepatitis B (P less than 0.001). Most of the delta infections (86 percent) were coinfections with hepatitis B virus; the balance were superinfections. Delta infection was strongly associated with fulminant hepatitis: 91 percent of patients with a fulminant outcome had delta infection, as compared with 45 percent of less severely ill drug abusers and their contacts (P = 0.0037). Alcohol, other drugs, and other hepatitis viruses could not be implicated as hepatotoxic cofactors for fulminant disease. This outbreak appeared to result from the concurrent spread of hepatitis B and delta viruses among new drug users. Control measures included the distribution to physicians of guidelines on prophylaxis in contacts of patients with hepatitis B, health education for drug abusers, and a hepatitis B vaccination program. Despite these efforts, the outbreak continued unabated until the number of new cases began to decline slowly in late 1986.

Entities:  

Mesh:

Year:  1987        PMID: 3670348     DOI: 10.1056/NEJM198711123172004

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  13 in total

1.  Blockade of neutrophil elastase attenuates severe liver injury in hepatitis B transgenic mice.

Authors:  Shinji Takai; Kiminori Kimura; Masahito Nagaki; Shinichi Satake; Kazuhiro Kakimi; Hisataka Moriwaki
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

Review 2.  Medical complications of intravenous drug use.

Authors:  M D Stein
Journal:  J Gen Intern Med       Date:  1990 May-Jun       Impact factor: 5.128

3.  Community-wide HIV counselling and testing in central Massachusetts: who is retested and does their behavior change?

Authors:  J McCusker; G Willis; M McDonald; S M Sereti; B F Lewis; J L Sullivan
Journal:  J Community Health       Date:  1996-02

4.  [4. Austrian consensus-statement for diagnosis and therapy of hepatitis B 2009].

Authors:  Markus Peck-Radosavljevic; Johann Deutsch; Peter Ferenci; Ivo Graziadei; Harald Hofer; Heidemarie Holzmann; Wolf-Dietrich Huber; Herman Laferl; Andreas Maieron; Rudolf Stauber; Wolfgang Vogel
Journal:  Wien Klin Wochenschr       Date:  2010-05-04       Impact factor: 1.704

5.  Estimation of the secondary attack rate for delta hepatitis coinfection among injection drug users.

Authors:  C Poulin; T Gyorkos; L Joseph
Journal:  Can J Infect Dis       Date:  1993-01

6.  Low prevalence of hepatitis B markers among Mexican female sex workers.

Authors:  L Juárez-Figueroa; F Uribe-Salas; C Conde-Glez; M Hernández-Avila; M Olamendi-Portugal; P Uribe-Zúñiga; E Calderón
Journal:  Sex Transm Infect       Date:  1998-12       Impact factor: 3.519

7.  Human hepatitis delta antigen is a nuclear phosphoprotein with RNA-binding activity.

Authors:  M F Chang; S C Baker; L H Soe; T Kamahora; J G Keck; S Makino; S Govindarajan; M M Lai
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

Review 8.  Delta hepatitis: molecular biology and clinical and epidemiological features.

Authors:  L B Polish; M Gallagher; H A Fields; S C Hadler
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

9.  Correlation of hepatitis B virus, hepatitis D virus and human immunodeficiency virus type I infection markers in hepatitis B surface antigen positive haemophiliacs and patients without haemophilia with clinical and histopathological outcome of hepatitis.

Authors:  N Wagner; H W Rotthauwe; M Becker; H P Dienes; T Mertens; H J Födisch; H H Brackmann
Journal:  Eur J Pediatr       Date:  1992-02       Impact factor: 3.183

10.  Viral hepatitis and the surgeon.

Authors:  G Y Minuk; A J Cohen; N Assy; M Moser
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.